• Vincristine Sulfate: Mechanistic Precision for Translational

  2026-04-30

  This thought-leadership article examines the mechanistic underpinnings and strategic deployment of vincristine sulfate in translational cancer research. By integrating mechanistic insight, validated protocol parameters, and cross-study synthesis—including evidence from anti-inflammatory drug repositioning—we provide actionable guidance for researchers advancing therapies in acute lymphoblastic leukemia, non-Hodgkin lymphoma, and beyond. The narrative differentiates itself by bridging microtubule disruption with systems-level workflow optimization, leveraging APExBIO’s Vincristine sulfate as a data-driven benchmark.

• Metabolomics Identifies Biomarkers of Carbapenem Resistance

  2026-04-30

  This study leverages LC-MS/MS metabolomics to rapidly distinguish carbapenemase-producing Enterobacterales (CPE) from non-CPE isolates using metabolite biomarkers. The findings have significant implications for advancing antibiotic resistance studies and diagnostic assay development.

• Host-Directed Therapy: GSK3 Inhibition in Tuberculosis Contr

  2026-04-29

  This study uncovers glycogen synthase kinase 3 (GSK3) inhibition as a viable host-directed therapy for controlling Mycobacterium tuberculosis (Mtb) infection. By leveraging kinase inhibitors, the research demonstrates effective suppression of intracellular Mtb growth and highlights new avenues for non-antibiotic intervention in tuberculosis.

• Nicotinamide Adenine Dinucleotide: Applied Workflows & Troub

  2026-04-29

  Nicotinamide Adenine Dinucleotide (NAD+) from APExBIO is central to advanced metabolic signaling and autophagy research, offering precise control in enzymatic and stress-response workflows. This guide delivers stepwise protocols, troubleshooting insights, and actionable interpretation of recent AMPK–autophagy breakthroughs to optimize your assays.

• Tamoxifen in Research: SERM-Driven Innovation & Protocol Mas

  2026-04-28

  Tamoxifen, a benchmark selective estrogen receptor modulator, powers reliable gene knockout and cancer biology models while enabling advanced kinase and antiviral assays. This guide delivers actionable workflows, troubleshooting insights, and highlights a cutting-edge CARM1-targeted approach to overcoming endocrine resistance.

• Angiotensin 1/2 (1-6): Applied Use-Cases in Cardiovascular &

  2026-04-28

  Angiotensin 1/2 (1-6) empowers researchers to dissect vascular tone regulation and investigate viral-host interactions with remarkable precision. Its validated use in both cardiovascular and emerging SARS-CoV-2 research opens new avenues for translational discovery. Explore advanced workflow optimizations, troubleshooting strategies, and evidence-based protocol enhancements below.

• Topotecan as First-Line Therapy for Small Cell Lung Cancer:

  2026-04-27

  This article analyzes the reference study's evaluation of topotecan in first-line treatment regimens for small cell lung cancer (SCLC), emphasizing its mechanistic novelty and manageable toxicity profile. Key findings are contextualized with current paradigms in topoisomerase inhibitor research and compared with insights from Irinotecan-focused studies in colorectal cancer models.

• Cy5 Maleimide (Non-sulfonated): Precision in Translational P

  2026-04-27

  Explore how Cy5 maleimide (non-sulfonated) unlocks site-specific protein labeling for next-generation translational research, with a focus on mechanistic insights, experimental strategies, and clinical impact. This article connects the latest findings in biomolecular condensate biology with actionable guidance for leveraging thiol-reactive fluorescent probes in precision workflows.

• Tropifexor (LJN452): Advanced FXR Modulation for Translation

  2026-04-26

  This article explores Tropifexor (LJN452) as a next-generation FXR agonist, synthesizing mechanistic insights and strategic recommendations for translational researchers. We contextualize its use in metabolic and liver disease models, highlight protocol best practices, and position APExBIO’s offering within the competitive landscape. By bridging foundational biology with actionable guidance, we chart new territory beyond conventional product summaries.

• Topotecan and Etoposide: Innovations in Topoisomerase Inhibi

  2026-04-25

  This article reviews the seminal work on topotecan, a topoisomerase I inhibitor, highlighting its mechanism, pharmacokinetics, and clinical impact. It contextualizes the findings alongside established topoisomerase II inhibitors such as Etoposide (VP-16), emphasizing the implications for DNA damage assays and cancer chemotherapy research.

• USP7-PKM2 Axis Governs Macrophage Polarization in Acute Panc

  2026-04-24

  This study uncovers how ubiquitin-specific protease 7 (USP7) modulates macrophage polarization and inflammation in severe acute pancreatitis (SAP) via PKM2-dependent metabolic reprogramming. The findings highlight PKM2 as a pivotal metabolic checkpoint in immune regulation and offer a mechanistic rationale for investigating PKM2 inhibitors in inflammatory disease models.

• LY294002: Selective PI3K Inhibitor for Cancer and Autophagy

  2026-04-24

  LY294002 (2-(4-Morpholinyl)-8-phenyl-4H-l-benzopyran-4-one) is a selective, reversible class I PI3K inhibitor widely used in cancer and autophagy research. This dossier details its mechanism, benchmarks, and workflow parameters with evidence-backed protocols.

• Ethacridine Lactate Monohydrate: Antiseptic Agent for Resear

  2026-04-23

  Ethacridine lactate monohydrate is a high-purity aromatic antiseptic compound, widely utilized as a research use antiseptic agent for microbial inhibition and control in biochemical and cellular assays. Its robust solubility profile and rapid action make it an asset for workflows demanding contamination prevention, especially in stem cell and epigenetic studies.

• Angiotensin (1-7): Reproducible Solutions for Cell Assays

  2026-04-23

  This article delivers scenario-driven, evidence-based guidance for leveraging Angiotensin (1-7) (SKU A1041) in cell viability and proliferation assays. It addresses real laboratory challenges—such as pathway specificity, solubility, and protocol optimization—by integrating product-quality data and peer-reviewed evidence. Researchers gain actionable strategies and workflow confidence with APExBIO's validated Angiotensin (1-7).

• Cefepime (BMY-28142): Precision Antimicrobial Profiling in C

  2026-04-22

  Explore how Cefepime (BMY-28142) enables next-generation profiling of antimicrobial activity against Gram-positive and Gram-negative bacteria in central nervous system infection research. This article uniquely bridges resistance analytics and neurotoxicity considerations for translational workflows.

15597 records 1/1040 page Next 12345 下5页 Last page